2026-10-12T04:57:26Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33995502 2026-10-01T14:54:36Z category_67901 portal_1154 item_type_7 month_year_10_2026

Congress Presentation: IMS 2026 Efficacy of elinzanetant in postmenopausal women with cardiometabolic comorbidities: a pooled analysis of Phase III OASIS-1 and -2 trials JoAnn V. Pinkerton (21671538) Nanette Santoro (2746333) Tommaso Simoncini (47466) Rebecca C. Thurston (16911868) Matthew Nudy (21566785) Senka Djordjevic (21842853) Ioanna Gkioni (21842866) Cecilia Caetano (18563210) James A. Simon (13763258) Menopause Elinzanetant cardiometabolic comorbidities OASIS-1 OASIS-2 Phase III postmenopause <p dir="ltr">In a subset of participants with CV or metabolic comorbidities at baseline, elinzanetant rapidly reduced VMS and improved sleep disturbances and menopause-related quality of life with sustained effect. Results are broadly consistent with the results of the overall population and support the use of elinzanetant in women with CV or metabolic comorbidities.</p> 2026-10-01T14:54:36Z Text Presentation 10.71943/bayer.figshare.33995502.v1 https://figshare.com/articles/presentation/Congress_Presentation_IMS_2026_Efficacy_of_elinzanetant_in_postmenopausal_women_with_cardiometabolic_comorbidities_a_pooled_analysis_of_Phase_III_OASIS-1_and_-2_trials/33995502 CC BY-ND